Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Date:3/7/2013

we achieve steady progress toward cash flow breakeven."

Financial ResultsFor the three months ended December 31, 2012, Cadence reported net product revenue of $17.1 million, an increase of $11.2 million from the $5.9 million of net product revenue reported for the three months ended December 31, 2011. For the twelve months ended December 31, 2012, the company reported net product revenue of $50.1 million, an increase of $38.6 million from the $11.5 million of net product revenue reported for 2011. Additionally, the company reported $0.1 million in licensing revenue during 2012, as compared to $5.2 million reported for 2011, primarily related to Cadence's data license agreement with Terumo Corporation, which intends to seek regulatory approval in Japan for the same intravenous formulation of acetaminophen as OFIRMEV.

For the three months ended December 31, 2012, Cadence reported a net loss of $21.4 million, or $0.25 per share, compared to a net loss of $27.6 million, or $0.37 per share, for the comparable period in 2011. For the twelve months ended December 31, 2012, the company's net loss was $81.0 million, or $0.95 per share, compared to a net loss of $93.0 million, or $1.41 per share, for the comparable period in 2011.

The net loss for each of the three and twelve months ended December 31, 2012, includes impairment charges and a loss on the sale of equipment totaling $8.6 million pertaining to certain assets involved with the manufacture of OFIRMEV under the terminated development and supply agreement with Baxter. Additionally, the Company recognized disposal costs of $0.3 million during the fourth quarter of 2012 for the inventory held as part of its manufacturing suspension at Baxter. Excluding these one-time charges, the company's net loss would have been $12.5 million, or $0.15 per share, for the three months ended December 31, 2012, and $72.1 million, or $0.84 per share, for the twelve months ended December 31, 2012.

The co
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
4. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
5. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
6. Cadence Pharmaceuticals to Host Analyst and Investor Day
7. Cadence to Open Finished Medical Device Facility
8. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
9. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Antigen Discovery Inc. (ADi), a ... , announced the receipt of a National Institutes of ... from the National Institute of Dental and Craniofacial Research (NIDCR). ... a Pan-HIV Protein Microarray Chip, which will contain every ... and aid in the development of safe and effective ...
(Date:10/22/2014)... 22, 2014   Reproductive Medicine Associates of ... the field of infertility, presents new clinical research ... The research abstract, released during the 70 th ... meeting in Honolulu, Hawaii , ... defect (SGD) pre-implantation genetic diagnosis (PGD). ...
(Date:10/22/2014)... Oct. 22, 2014  Paper Pak Industries, a ... APLS ® Body Guard Bio, a disposable, ... of bacteria and virus while protecting service providers ... Bio features a rugged, external nylon shell, watertight ... a leak-proof inner chamber that contains contaminated and ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2
... New Studies Highlight Potential Benefit of Unique ... -- Stimulant drug abuse,remains an ongoing concern ... treat Attention Deficit Hyperactivity Disorder,(ADHD). Data presented ... of,the American Psychiatric Association highlighted findings that,long-acting ...
... Austria, May 23, 2007-The chemotherapy drug,docetaxel currently offers ... the result of a now,published clinical trial that ... chemotherapy drugs. When using docetaxel, the risk of,disease ... when using the,next-best chemotherapy drug. , The use ...
Cached Medicine Technology:New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 2New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 3New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 4New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 5Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of,Docetaxel Chemotherapy 2Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of,Docetaxel Chemotherapy 3
(Date:10/22/2014)... Los Angeles, California (PRWEB) October 22, 2014 ... Recovery 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; ... the field of Yoga & Recovery. This book is ... and thrive in a life of recovery. , Recovery ... of the 12 Steps; Recovery 2.0 is a guide for ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... Although there are only 24 hours in a day, ... have trouble finding time within their busy schedules for exercise and ... of time to get in shape. Here are five ways you ... , Change Up Your Commute , Consider riding a bike ... exercise into your daily routine. If you must use your car ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... risk of post-traumatic stress, study finds, , , THURSDAY, ... children in pediatric intensive care units experience delusions, and ... of developing post-traumatic stress syndrome after their hospital stay. ... to be sedated for more than two days, and ...
... Palomid 529 as an inhibitor of macular degeneration, diabetic ... ... Mass., May 1 Paloma Pharmaceuticals,Inc. today announced it has ... for Research in Vision and Ophthalmology (ARVO),describing the activity of ...
... CONSHOHOCKEN, Pa., May 1 Cadient Group, the,premier ... today it has appointed Barbara Dowling as Senior ... the healthcare,vertical on both the client and agency ... digital channel to address business critical,issues. In this ...
... 1 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today ... 2008 results conference call and Annual Meeting of Shareholders., ... May 8 at 8:30 a.m. (ET) Labopharm will host ... results. Labopharm will,report its first quarter 2008 financial results ...
... N.Y., May 1 Gentiva Health,Services, Inc. (Nasdaq: GTIV ... reported the following financial,results for the first quarter ended March ... ), -- Net revenues increased 8% to $323.7 million ... 1, 2007. -- Net income increased 13% to $7.7 ...
... three children admitted to pediatric intensive care will experience ... for post-traumatic stress symptoms, according to a new study ... (PICU). , The study, which appears in the ... Respiratory and Critical Care Medicine, published by the American ...
Cached Medicine News:Health News:Delusions Common in Pediatric ICU 2Health News:Delusions Common in Pediatric ICU 3Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 2Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 3Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 4Health News:Cadient Group Appoints Barbara Dowling to Senior Vice President Customer Engagements 2Health News:Labopharm announces details for first quarter results conference call and annual meeting 2Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 2Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 3Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 4Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 5Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 6Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 7Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 8Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 9Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 10Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 11Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 12Health News:Haunted by hallucinations: Children in the PICU traumatized by delusions 2
... Avaulta™ BioSynthetic Mesh is ... coated in the central ... hydrophilic film of porcine ... of the Avaulta™ BioSynthetic ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
... is a soft monofilament ... be used for a ... procedures, including cystocele, rectocele, ... yet strong, POPmeshs flexibility ...
... Hydrix XM is a ... pericardium, a material known for ... sourcing and manufacturing procedures ensure ... safety. Caldera's patented processing enhances ...
Medicine Products: